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Introduction
 Will address three questions
•How has financial downturn affected the VC industry?
•How have VCs responded?
•What are the implications for biosciences development?      
 First:
•Brief description of VC investing model
•Background on RiverVest
2
Venture Capital Investing
 Raise commitments from institutional and high-net-worth individual investors
• Endowments
• Foundations
• Pension Funds
 Invest these funds in privately-held, technology-based companies participating 
in high-growth industries  
• IT/software
• Life sciences
• Cleantech
 Support entrepreneurs leading these companies in building businesses that  
can be sold to strategic investors or taken public through an IPO within 
specified timeframe
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Heaviest venture funded industries in the U S today are software -     . .   , 
energy, biotech and medical devices 
2008
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Source: PricewarehouseCoopers/National Venture Capital Association MoneyTree TM Report
Life sciences share of total has grown by 50%        
in last decade from 20 to 30%
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Source: PricewarehouseCoopers/National Venture Capital Association MoneyTree TM Report
RiverVest Venture Partners
• Focus on life science investing (medical device, biopharma)
• Team with extensive research, clinical, operational, and investment expertise  
committed to helping entrepreneurs build successful companies
• Two funds totaling $165 million in capital; investments in more than 20 portfolio 
companies
• Flexible with respect to stage; currently focused on later-stage opportunities, 
but have founded six companies in the past
• Located in St. Louis, MO
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I. How has financial downturn affected VC industry?        
 Slowdown in exit activity
•IPOs of VC-backed companies almost non-existent
9
IPO levels in numbers and dollars were down dramatically        
in 2008 and 2009
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Source: Thomson Reuters/National Venture Capital Association 
I H h fi i l d t ff t d VC i d t ?.  ow as nanc a  own urn a ec e   n us ry
 Slowdown in exit activity
• IPOs of VC-backed companies almost non-existent
• Strategic acquisition activity also down, as are total proceeds
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Number of acquisitions of venture-backed companies down 30% 
in 2009 vs 2007
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Source: Thomson Reuters/National Venture Capital Association 
Aggregate acquisition proceeds down almost 60% 2009 vs 2007
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Based on limited sample acquisition proceeds in 2009 were less   ,       
than dollars invested in 40% of transactions
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Source: Thomson Reuters/National Venture Capital Association 
I H h fi i l d t ff t d VC i d t ?.  ow as nanc a  own urn a ec e   n us ry
 Slowdown in exit activity
• IPOs of VC-backed companies almost non-existent
• Strategic acquisition activity also down, as is pricing of deals
 VC f d i i d d ti ll i 2009 un ra s ng own rama ca y n 
• Numerator effect associated with fewer exits/distributions
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VC fundraising down somewhat in 2008 but almost     ,   
40% in 2009
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Source: Thomson Reuters/NVCA
I How has financial downturn affected VC industry?.        
 Slowdown in exit activity
• IPOs of VC-backed companies almost non-existent
• Strategic acquisition activity also down, as is pricing of deals
 VC f d i i d d ti ll i 2009 un ra s ng own rama ca y n 
• Numerator effect associated with fewer exits/distributions  
• Denominator effect associated with decline in value of publicly-traded 
iti f d t hi hsecur es rom pre- own urn g s
• Premium on liquidity in an over-leveraged economy
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Private investments of five major university endowments      
6/30/2008
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II. How have VCs responded?     
 Cut back on investment activity
• Culled portfolios 
• Marshaled reserves to support existing portfolio companies
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Despite recession Q4 VCs funded 1 202 new companies in 2008  ,   ,     , 
but number funded down 40% in 2009 
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VC dollar investment was down only 8% in 2008        ,  
but down another 35% in 2009
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Source: PricewarehouseCoopers/National Venture Capital Association MoneyTree TM Report
II H h VC d d?.  ow ave s respon e
 Cut back on investment activity
• Culled portfolios 
• Marshaled reserves to support existing portfolio companies
• Slowed down pace/reduced size of investments in new portfolio companies
 Focus on later-stage opportunities
• Need to provide support to companies that haven’t exited  
• Attractive valuations
• Prospect of earlier future exits 
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Share of later stage deals has tripled in last year
Metric 1995 1998 Most recent 4 qtrs*-    
# Venture Deals/Year 2,802 2,814
# Later Stage Deals/Year 311 848
Source: PricewarehouseCoopers/National Venture Capital Association MoneyTree TM Report
Later as % of Deals 11.1% 30.1%
* Through 3Q 2009
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II. How have VCs responded?     
 Cut back on investment activity
• Culled portfolios
• Marshaled reserves to support existing portfolio companies
• Slowed down pace/reduced size of investments in new portfolio companies
 Focus on later-stage opportunities   
• Need to provide support to companies that haven’t exited  
• Attractive valuations
P t f li i t• rospec  o  ear er ex s  
 Closed up shop
• Number of VC firms falling
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• Capital under management declining
The number of US VC firms and managed capital have declined by 22%
and 35%, respectively, from 2006 to 2009
At Year 
End
# Venture
Firms
Capital Under 
Management
1970 28 $1B   
1980 91     $4B
1990 390   $29B
2000 882 $225B
2006 1022 $277B
2009 794 $179B
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Source: 2008 NVCA Yearbook, prepared by Thomson Reuters, figure 1.04
III.  What are implications for bioscience development?
 Growing funding gap between founding and becoming venture-ready
 Heightened capital risk for private, venture-backed companies, particularly  
those at an early-stage
 Need to access alternative funding sources         
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What alternative sources are there?
 R01 grants
 R l i l NIH Cli i l d T l i l S i A d (“CTSA ”)e at ve y new  n ca  an  rans at ona  c ence war s s
 University funds, like WUSTL’s Bear Cub Fund
 Other community-based funding like that from BioGenerator in St Louis  ,     . 
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What alternative sources are there? (cont.)
 Corporate research collaborations
 SBIR/STTR grants after startup company founded
 Angel funding
• St. Louis Arch Angels   
• Mid-America Angels (Kansas City)
• Centennial Angels (Columbia)
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IV. Conclusions  
 Recent financial downturn created short-term dislocations in the capital 
markets and exposed longer-term issues, like inadequate attention to liquidity
 Focus on liquidity has had a particularly adverse impact on private investments
 Accordingly, access to venture capital for early-stage technologies is even
more difficult than it had been     
 This has encouraged doing more development under the university umbrella, 
a trend that was already underway
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IV. Conclusions (cont.)    
 It is also encouraging established businesses to consider expenditures on 
earlier-stage technologies, often in collaboration with universities, to assure a 
f future pipeline o  opportunities
 Could imply more licensing deals with established businesses and fewer 
startups, at least for a time
 Innovative technologies will remain a key factor in assuring the future 
competitiveness and growth of the U.S.; those with merit will ultimately be    
funded, but the process won’t be easy
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Q estions?u
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